International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily - Update 2023 .
Thomas P BurrisIan Mitchelle S de VeraIsabelle CoteColin A FlavenyUdayanga S WanninayakeArindam ChatterjeeJohn K WalkerNickolas SteinauerJinsong ZhangLaurel A CoonsKenneth S KorachDerek W CainAnthony N HollenbergPaul WebbDouglas ForrestAnton M JettenDean P EdwardsSandra L GrimmSean HartigCarol A LangeJennifer K RicherCarol A SartoriusMarc TetelCyrielle BillonBahaa ElgendyLamees HegazyKristine GriffettNahuel PeinettiKerry L BurnsteinTravis S HughesSadichha SitaulaKeith R StayrookAlexander CulverMeghan H MurrayBrian N FinckJohn A CidlowskiPublished in: Pharmacological reviews (2023)
The nuclear receptor (NR) superfamily comprises 48 transcription factors in humans that control a plethora of gene network programs involved in a wide range of physiological processes. In this review, we will summarize and discuss recent progress in NR biology and drug development derived from the integration of various approaches, including biophysical techniques, structural studies, and translational investigations. We also highlight how defective NR signaling results in various diseases and disorders and how NRs can be targeted for therapeutic intervention via modulation via binding to synthetic lipophilic ligands. Furthermore, we also review recent studies that improved our understanding of NR structure and signaling. Significance Statement Nuclear receptors are ligand regulated transcription factors that function as key regulators of a wide range of physiological functions. NRs also serve as receptors for myriad drugs and in this review we provide an update of recent research into the function of this family of drug targets.